Search

Your search keyword '"Pajkrt, Dasja"' showing total 679 results
Start Over Author "Pajkrt, Dasja"
679 results on '"Pajkrt, Dasja"'

1. Prospective multicenter evaluation of adherence to the Dutch guideline for children aged 0–16 years with fever without a source—febrile illness in children (FINCH) study

Author

Keuning, Maya W., Klarenbeek, Nikki N., Bout, Hidde J., Broer, Amber, Draaijer, Melvin, Hol, Jeroen, Hollander, Nina, Merelle, Marieke, Nassar-Sheikh Rashid, Amara, Nusman, Charlotte, Oostenbroek, Emma, Ridderikhof, Milan L., Roelofs, Manouck, van Rossem, Ellen, van der Schoor, Sophie R. D., Schouten, Sarah M., Taselaar, Pieter, Vasse, Koen, van Wermeskerken, Anne-Marie, van der Zande, Julia M. J., Zuurbier, Roy, Bijlsma, Merijn W., Pajkrt, Dasja, and Plötz, Frans B.

Published
2024
Full Text
View/download PDF

3. Correction to: Prospective multicenter evaluation of adherence to the Dutch guideline for children aged 0–16 years with fever without a source—febrile illness in children (FINCH) study

Author

Keuning, Maya W., Klarenbeek, Nikki N., Bout, Hidde J., Broer, Amber, Draaijer, Melvin, Hol, Jeroen, Hollander, Nina, Merelle, Marieke, Nassar-Sheikh Rashid, Amara, Nusman, Charlotte, Oostenbroek, Emma, Ridderikhof, Milan L., Roelofs, Manouck, van Rossem, Ellen, van der Schoor, Sophie R. D., Schouten, Sarah M., Taselaar, Pieter, Vasse, Koen, van Wermeskerken, Anne-Marie, van der Zande, Julia M. J., Zuurbier, Roy, Bijlsma, Merijn W., Pajkrt, Dasja, and Plötz, Frans B.

Published
2024
Full Text
View/download PDF

6. Transient anti-cytokine autoantibodies superimpose the hyperinflammatory response in Kawasaki disease and multisystem inflammatory syndrome in children: a comparative cohort study on correlates of disease

Author

Hendriks, T., Felderhof, M.K., Weggelaar, N.M., Filippini, L., Rozendaal, L., Groeneweg, M., Nuboer, R., Bruijn, M., Dolman, K.M., Noordzij, J.G., de Winter, J.P., Vlieger, A.M., Plötz, F.B., Delemarre, L.C., Netea, Stejara A., Biesbroek, Giske, van Stijn, Diana, Ijspeert, Hanna, van der Made, Caspar I., Jansen, Machiel H., Geissler, Judy, van den Berg, J.M. (Merlijn), van der Kuip, Martijn, Gruppen, Mariken P., Schonenberg-Meinema, Dieneke, Kapitein, Berber, van Furth, A.M. (Marceline) Tutu, Nagelkerke, Sietse Q., Pajkrt, Dasja, Plötz, Frans B., den Boer, M.E.J. (Lisette), Landman, Gijs W., van Houten, Marlies A., Goetschalckx, Ines, Toonen, Erik J.M., van de Veerdonk, Frank L., Kuipers, Irene M., Dik, Willem A., and Kuijpers, Taco W.

Published
2023
Full Text
View/download PDF

7. Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents

Author

van Genderen, Jason G, Van den Hof, Malon, de Boer, Claudia G, Jansen, Hans PG, van Deventer, Sander JH, Tsimikas, Sotirios, Witztum, Joseph L, Kastelein, John JP, and Pajkrt, Dasja

Subjects
Microbiology, Biological Sciences, Pediatric Research Initiative, Clinical Research, Cardiovascular, Heart Disease, Atherosclerosis, Infectious Diseases, Prevention, HIV/AIDS, Pediatric, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, Adolescent, Cardiovascular Diseases, Child, Child, Preschool, Cohort Studies, Dyslipidemias, Ethnicity, Female, HIV, HIV Infections, Humans, Lipoprotein(a), Longitudinal Studies, Male, Risk Factors, Young Adult, human immunodeficiency virus, cardiovascular disease, apolipoproteins dyslipidemia, atherosclerotic cardiovascular disease
Abstract

HIV is an independent risk factor of cardiovascular disease (CVD); therefore, perinatally HIV-infected (PHIV) children potentially have a greater CVD risk at older age. Lipoprotein(a) (Lp(a)) is an established risk factor for CVD in the general population. To evaluate a potential increased CVD risk for PHIV children, we determined their lipid profiles including Lp(a). In the first substudy, we assessed the lipid profiles of 36 PHIV children visiting the outpatient clinic in Amsterdam between 2012 and 2020. In the second substudy, we enrolled 21 PHIV adolescents and 23 controls matched for age, sex and ethnic background on two occasions with a mean follow-up time of 4.6 years. We assessed trends of lipid profiles and their determinants, including patient and disease characteristics, using mixed models. In the first substudy, the majority of PHIV children were Black (92%) with a median age of 8.0y (5.7-10.8) at first assessment. Persistent elevated Lp(a) levels were present in 21/36 (58%) children (median: 374 mg/L (209-747); cut off = 300). In the second substudy, the median age of PHIV adolescents was 17.5y (15.5-20.7) and of matched controls 16.4y (15.8-19.5) at the second assessment. We found comparable lipid profiles between groups. In both studies, increases in LDL-cholesterol and total cholesterol were associated with higher Lp(a) levels. A majority of PHIV children and adolescents exhibited elevated Lp(a) levels, probably associated with ethnic background. Nonetheless, these elevated Lp(a) levels may additionally contribute to an increased CVD risk.

Published
2021

12. Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls

Author

Van den Hof, Malon, Haneveld, Mirthe J Klein, Blokhuis, Charlotte, Scherpbier, Henriette J, Jansen, Hans PG, Kootstra, Neeltje A, Dallinga-Thie, Geesje M, Van Deventer, Sander JH, Tsimikas, Sotirios, Pajkrt, Dasja, Van den Hof, M, Blokhuis, C, Cohen, S, Pajkrt, D, Scherpbier, HJ, Kuijpers, TW, van der Plas, A, Weijsenfeld, A, Stege, JS ter, Kootstra, NA, Caan, MWA, Mutsaerts, HJMM, Majoie, CBLM, Demirkaya, N, Verbraak, FD, Schmand, B, Geurtsen, G, Mathot, RAA, Wit, FWNM, Reiss, P, Teunissen, CE, Kuhle, J, and Meijer, JCM

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Pediatric, Clinical Research, Atherosclerosis, Prevention, Infectious Diseases, Heart Disease, Good Health and Well Being, cardiovascular disease risk, lipids, lipoprotein(a), MRI, perinatal HIV infection, NOVICE study group, Clinical sciences, Medical microbiology
Abstract

BackgroundHIV-associated cardiovascular disease (CVD) risk in combination antiretroviral therapy (cART)-treated perinatally HIV-infected patients (PHIV+) remains unknown due to the young age of this population. Lipoprotein(a) (Lp(a)) has been established as an independent causal risk factor for CVD in the general population but has not been well established in the population of PHIV+.MethodsWe cross-sectionally compared lipid profiles, including nonfasting Lp(a), together with total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides between 35 cART-treated PHIV+ children aged 8-18 years and 37 controls who were matched for age, sex, ethnicity, and socioeconomic status. We explored associations between Lp(a) and disease- and treatment-related factors (inflammation, monocyte activation, and vascular), biomarkers, and neuroimaging outcomes using linear regression models.ResultsPHIV+ children had significantly higher levels of Lp(a) compared with controls (median, 43.6 [21.6-82.4] vs 21.8 [16.8-46.6] mg/dL; P = .033). Other lipid levels were comparable between groups. Additional assessment of apolipoprotein B, apolipoprotein CIII, apolipoprotein E, and APOE genotype revealed no significant differences. Higher Lp(a) levels were associated with higher plasma apoB levels and with lower monocyte chemoattractant protein-1 and TG levels in PHIV+ children. Lp(a) was not associated with HIV- or cART-related variables or with neuroimaging outcomes.ConclusionscART-treated PHIV+ children appear to have higher levels of Lp(a) compared with ethnicity-matched controls, which may implicate higher CVD risk in this population. Future research should focus on the association between Lp(a) and (sub)clinical CVD measurements in cART-treated PHIV+ patients.Dutch trial register numberNRT4074.

Published
2019

16. Neurofilament light protein as a biomarker for spinal muscular atrophy: A review and reference ranges

Author

CTI Nierkens, Infection & Immunity, Bayoumy, Sherif, Verberk, Inge M.W., Vermunt, Lisa, Willemse, Eline, Den Dulk, Ben, Van Der Ploeg, Ans T., Pajkrt, Dasja, Nitz, Elisa, Van Den Hout, Johanna M.P., Van Der Post, Julie, Wolf, Nicole I., Beerepoot, Shanice, Groen, Ewout J.N., Tüngler, Victoria, Teunissen, Charlotte E., CTI Nierkens, Infection & Immunity, Bayoumy, Sherif, Verberk, Inge M.W., Vermunt, Lisa, Willemse, Eline, Den Dulk, Ben, Van Der Ploeg, Ans T., Pajkrt, Dasja, Nitz, Elisa, Van Den Hout, Johanna M.P., Van Der Post, Julie, Wolf, Nicole I., Beerepoot, Shanice, Groen, Ewout J.N., Tüngler, Victoria, and Teunissen, Charlotte E.

Published
2024

17. Neurofilament light protein as a biomarker for spinal muscular atrophy:A review and reference ranges

Author

Bayoumy, Sherif, Verberk, Inge M.W., Vermunt, Lisa, Willemse, Eline, Den Dulk, Ben, Van Der Ploeg, Ans T., Pajkrt, Dasja, Nitz, Elisa, Van Den Hout, Johanna M.P., Van Der Post, Julie, Wolf, Nicole I., Beerepoot, Shanice, Groen, Ewout J.N., Tüngler, Victoria, Teunissen, Charlotte E., Bayoumy, Sherif, Verberk, Inge M.W., Vermunt, Lisa, Willemse, Eline, Den Dulk, Ben, Van Der Ploeg, Ans T., Pajkrt, Dasja, Nitz, Elisa, Van Den Hout, Johanna M.P., Van Der Post, Julie, Wolf, Nicole I., Beerepoot, Shanice, Groen, Ewout J.N., Tüngler, Victoria, and Teunissen, Charlotte E.

Abstract

Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, characterized by progressive neuromuscular degeneration resulting from mutations in the survival motor neuron (SMN1) gene. The availability of disease-modifying therapies for SMA therapies highlights the pressing need for easily accessible and cost-effective blood biomarkers to monitor treatment response and for better disease management. Additionally, the wide implementation of newborn genetic screening programs in Western countries enables presymptomatic diagnosis of SMA and immediate treatment administration. However, the absence of monitoring and prognostic blood biomarkers for neurodegeneration in SMA hinders effective disease management. Neurofilament light protein (NfL) is a promising biomarker of neuroaxonal damage in SMA and reflects disease progression in children with SMA undergoing treatment. Recently, the European Medicines Agency issued a letter of support endorsing the potential utilization of NfL as a biomarker of pediatric neurological diseases, including SMA. Within this review, we comprehensively assess the potential applications of NfL as a monitoring biomarker for disease severity and treatment response in pediatric-onset SMA. We provide reference ranges for normal levels of serum based NfL in neurologically healthy children aged 0-18 years. These reference ranges enable accurate interpretation of NfL levels in children and can accelerate the implementation of NfL into clinical practice.

Published
2024

18. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges.

Author

Bayoumy, Sherif, Verberk, Inge M.W., Vermunt, Lisa, Willemse, Eline, den Dulk, Ben, van der Ploeg, Ans T., Pajkrt, Dasja, Nitz, Elisa, van den Hout, Johanna M.P., van der Post, Julie, Wolf, Nicole I., Beerepoot, Shanice, Groen, Ewout J.N., Tüngler, Victoria, and Teunissen, Charlotte E.

Subjects
SPINAL muscular atrophy, BIOMARKERS, CYTOPLASMIC filaments, PROGNOSIS, GENETIC testing, DYSTROPHY
Abstract

Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, characterized by progressive neuromuscular degeneration resulting from mutations in the survival motor neuron (SMN1) gene. The availability of disease-modifying therapies for SMA therapies highlights the pressing need for easily accessible and cost-effective blood biomarkers to monitor treatment response and for better disease management. Additionally, the wide implementation of newborn genetic screening programs in Western countries enables presymptomatic diagnosis of SMA and immediate treatment administration. However, the absence of monitoring and prognostic blood biomarkers for neurodegeneration in SMA hinders effective disease management. Neurofilament light protein (NfL) is a promising biomarker of neuroaxonal damage in SMA and reflects disease progression in children with SMA undergoing treatment. Recently, the European Medicines Agency issued a letter of support endorsing the potential utilization of NfL as a biomarker of pediatric neurological diseases, including SMA. Within this review, we comprehensively assess the potential applications of NfL as a monitoring biomarker for disease severity and treatment response in pediatric-onset SMA. We provide reference ranges for normal levels of serum based NfL in neurologically healthy children aged 0–18 years. These reference ranges enable accurate interpretation of NfL levels in children and can accelerate the implementation of NfL into clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies

Author

Mutsaerts, Henk J.M.M., Petr, Jan, Groot, Paul, Vandemaele, Pieter, Ingala, Silvia, Robertson, Andrew D., Václavů, Lena, Groote, Inge, Kuijf, Hugo, Zelaya, Fernando, O’Daly, Owen, Hilal, Saima, Wink, Alle Meije, Kant, Ilse, Caan, Matthan W.A., Morgan, Catherine, de Bresser, Jeroen, Lysvik, Elisabeth, Schrantee, Anouk, Bjørnebekk, Astrid, Clement, Patricia, Shirzadi, Zahra, Kuijer, Joost P.A., Wottschel, Viktor, Anazodo, Udunna C., Pajkrt, Dasja, Richard, Edo, Bokkers, Reinoud P.H., Reneman, Liesbeth, Masellis, Mario, Günther, Matthias, MacIntosh, Bradley J., Achten, Eric, Chappell, Michael A., van Osch, Matthias J.P., Golay, Xavier, Thomas, David L., De Vita, Enrico, Bjørnerud, Atle, Nederveen, Aart, Hendrikse, Jeroen, Asllani, Iris, and Barkhof, Frederik

Published
2020
Full Text
View/download PDF

26. Assessment of The Broad-Spectrum Host Targeting Antiviral Efficacy of Halofuginone Hydrobromide in Human Airway, Intestinal and Brain Organoid Models

Author

García-Rodríguez, Inés, primary, Moreni, Giulia, additional, Capendale, Pamela E., additional, Mulder, Lance, additional, Aknouch, Ikrame, additional, Vieira de Sá, Renata, additional, Johanneson, Nina, additional, Freeze, Eline, additional, van Eijk, Hetty, additional, Koen, Gerrit, additional, Wolthers, Katja, additional, Pajkrt, Dasja, additional, Sridhar, Adithya, additional, and Calitz, Carlemi, additional

Published
2023
Full Text
View/download PDF

27. First description and phylogenetic analysis of coxsackie virus A non‐polio enteroviruses and parechoviruses A in South Sudanese children

Author

Couderé, Karen, primary, Benschop, Kimberley, additional, van Steen, Astrid, additional, Verweij, Jaco J., additional, Pas, Suzan, additional, Cremer, Jeroen, additional, Edridge, Arthur W. D., additional, Abd‐Elfarag, Gasim O. E., additional, van Hensbroek, Michaël B., additional, Pajkrt, Dasja, additional, Murk, Jean‐Luc, additional, and Wolthers, Katja C., additional

Published
2023
Full Text
View/download PDF

29. Transient anti-cytokine autoantibodies superimpose the hyperinflammatory response in Kawasaki disease and multisystem inflammatory syndrome in children: a comparative cohort study on correlates of disease

Author

Netea, Stejara A., primary, Biesbroek, Giske, additional, van Stijn, Diana, additional, Ijspeert, Hanna, additional, van der Made, Caspar I., additional, Jansen, Machiel H., additional, Geissler, Judy, additional, van den Berg, J.M. (Merlijn), additional, van der Kuip, Martijn, additional, Gruppen, Mariken P., additional, Schonenberg-Meinema, Dieneke, additional, Kapitein, Berber, additional, van Furth, A.M. (Marceline) Tutu, additional, Nagelkerke, Sietse Q., additional, Pajkrt, Dasja, additional, Plötz, Frans B., additional, den Boer, M.E.J. (Lisette), additional, Landman, Gijs W., additional, van Houten, Marlies A., additional, Goetschalckx, Ines, additional, Toonen, Erik J.M., additional, van de Veerdonk, Frank L., additional, Kuipers, Irene M., additional, Dik, Willem A., additional, Kuijpers, Taco W., additional, Hendriks, T., additional, Felderhof, M.K., additional, Weggelaar, N.M., additional, Filippini, L., additional, Rozendaal, L., additional, Groeneweg, M., additional, Nuboer, R., additional, Bruijn, M., additional, Dolman, K.M., additional, Noordzij, J.G., additional, de Winter, J.P., additional, Vlieger, A.M., additional, Plötz, F.B., additional, and Delemarre, L.C., additional

Published
2023
Full Text
View/download PDF

31. Reply to Vos et al

Author

Bruning, Andrea H.L., Leeflang, Mariska M.G., Wolthers, Katja C., and Pajkrt, Dasja

Published
2017

32. Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States

Author

Karelehto, Eveliina, Brouwer, Lieke, Benschop, Kimberley, Kok, Jen, Basile, Kerri, McMullan, Brendan, Rawlinson, William, Druce, Julian, Nicholson, Suellen, Selvarangan, Rangaraj, Harrison, Christopher, Lankachandra, Kamani, van Eijk, Hetty, Koen, Gerrit, de Jong, Menno, Pajkrt, Dasja, and Wolthers, Katja C.

Subjects
Picornaviruses -- Distribution, Prevalence studies (Epidemiology), Public health administration -- Methods, Diarrhea, Newborn infants, Infants, Meningitis, Infection, Epidemiology, Pediatric diseases, Paralysis, B cells, Antibodies, Company distribution practices, Health
Abstract

Parechovirus A3 (PeV-A3), belonging to the Picornavirus family, can cause respiratory and gastrointestinal symptoms, as well as meningitis and sepsis-like disease in infants (1). PeV-A3 was isolated from a fecal [...]

Published
2019
Full Text
View/download PDF

40. Amino acid variation at VP1-145 of enterovirus A71 determines the viral infectivity and receptor usage in a primary human intestinal model

Author

Aknouch, Ikrame, primary, García-Rodríguez, Inés, additional, Giugliano, Francesca Paola, additional, Calitz, Carlemi, additional, Koen, Gerrit, additional, van Eijk, Hetty, additional, Johannessson, Nina, additional, Rebers, Sjoerd, additional, Brouwer, Lieke, additional, Muncan, Vanesa, additional, Stittelaar, Koert J., additional, Pajkrt, Dasja, additional, Wolthers, Katja C., additional, and Sridhar, Adithya, additional

Published
2023
Full Text
View/download PDF

44. Amino acid variation at VP1-145 of enterovirus A71 determines the viral infectivity and receptor usage in a primary human intestinal model

Author

Aknouch, Ikrame, García-Rodríguez, Inés, Giugliano, Francesca Paola, Calitz, Carlemi, Koen, Gerrit, van Eijk, Hetty, Johannessson, Nina, Rebers, Sjoerd, Brouwer, Lieke, Muncan, Vanesa, Stittelaar, Koert J., Pajkrt, Dasja, Wolthers, Katja C., Sridhar, Adithya, Aknouch, Ikrame, García-Rodríguez, Inés, Giugliano, Francesca Paola, Calitz, Carlemi, Koen, Gerrit, van Eijk, Hetty, Johannessson, Nina, Rebers, Sjoerd, Brouwer, Lieke, Muncan, Vanesa, Stittelaar, Koert J., Pajkrt, Dasja, Wolthers, Katja C., and Sridhar, Adithya

Abstract

Enterovirus A71 (EV-A71) can elicit a wide variety of human diseases such as hand, foot, and mouth disease and severe or fatal neurological complications. It is not clearly understood what determines the virulence and fitness of EV-A71. It has been observed that amino acid changes in the receptor binding protein, VP1, resulting in viral binding to heparan sulfate proteoglycans (HSPGs) may be important for the ability of EV-A71 to infect neuronal tissue. In this study, we identified that the presence of glutamine, as opposed to glutamic acid, at VP1-145 is key for viral infection in a 2D human fetal intestinal model, consistent with previous findings in an airway organoid model. Moreover, pre-treatment of EV-A71 particles with low molecular weight heparin to block HSPG-binding significantly reduced the infectivity of two clinical EV-A71 isolates and viral mutants carrying glutamine at VP1-145. Our data indicates that mutations in VP1 leading to HSPG-binding enhances viral replication in the human gut. These mutations resulting in increased production of viral particles at the primary replication site could lead to a higher risk of subsequent neuroinfection. Importance: With the near eradication of polio worldwide, polio-like illness (as is increasingly caused by EV-A71 infections) is of emerging concern. EV-A71 is indeed the most neurotropic enterovirus that poses a major threat globally to public health and specifically in infants and young children. Our findings will contribute to the understanding of the virulence and the pathogenicity of this virus. Further, our data also supports the identification of potential therapeutic targets against severe EV-A71 infection especially among infants and young children. Furthermore, our work highlights the key role of HSPG-binding mutations in the disease outcome of EV-A71. Additionally, EV-A71 is not able to infect the gut (the primary replication site in humans) in traditionally used animal models. Thus, our research highli

Published
2023

45. Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands

Author

Van Den Hof, Malon, Smit, Colette, Van Rossum, Annemarie M.C., Fraaij, Pieter L.A., Wolfs, Tom F.W., Geelen, Sibyl P.M., Scherpbier, Henriette J., Schölvinck, Elisabeth H., Van Aerde, Koen, Reiss, Peter, Wit, Ferdinand W.N.M., Pajkrt, Dasja, Van Den Hof, Malon, Smit, Colette, Van Rossum, Annemarie M.C., Fraaij, Pieter L.A., Wolfs, Tom F.W., Geelen, Sibyl P.M., Scherpbier, Henriette J., Schölvinck, Elisabeth H., Van Aerde, Koen, Reiss, Peter, Wit, Ferdinand W.N.M., and Pajkrt, Dasja

Abstract

Objectives To provide an overview of the demographics, treatment characteristics and long-term outcomes of children with perinatal HIV-1 infection (PHIV) living in the Netherlands (NL) and to specifically investigate whether outcomes differ by children's adoption status. Design A prospective population-based open cohort including children with PHIV in NL. Methods We included children with PHIV who had entered HIV care in NL since 2007, in view of a sharp increase in the number of adopted children with PHIV since that year. We compared the proportion with virologic suppression and CD4+T-cell count over time between the following groups of children with PHIV: adopted and born outside NL, non-adopted born in NL, and non-adopted born outside NL, using generalized estimating equations and linear mixed effects models, respectively. To account for the variation in cohort inclusion, we analyzed data of children exposed to at least one year of antiretroviral therapy (ART). Results We included 148 children (827.5 person-years of follow-up, 72% adopted, age at start care in NL 2.4 (0.5-5.3)). Under-18 mortality was zero. Over the years, a boosted PI-based regimen was most often prescribed. The use of integrase inhibitors increased since 2015. Nonadopted children born in NL were less likely to achieve virological suppression compared to adopted children (OR 0.66, 95%CI 0.51-0.86, p = 0.001), which disappeared after excluding one child with suspected treatment nonadherence (OR 0.85, 95%CI 0.57-1.25, p = 0.400). CD4+T-cell Z-score trajectories were not significantly different between groups. Conclusions Despite considerable and increasing diversity of the population of children with PHIV in NL, geographical origin and adoption status do not seem to pose important challenges in achieving good immunological and virological outcomes.

Published
2023

47. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care

Author

Dutch HIV Adolescents and Young Adults (AYA) Study Group, Weijsenfeld, Annouschka M., Smit, Colette, Cohen, Sophie, Wit, Ferdinand W. N. M., Mutschelknauss, Michelle, van der Knaap, Linda C., van Zonneveld, Laura M., Zomer, Bert J., Nauta, Nike, Patist, Joke C., Kuipers-Jansen, Marien H. J., Smit, Esther P., Blokhuis, Charlotte, and Pajkrt, Dasja

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results